SillaJen’s Novel HCC Therapy Set For Phase III
This article was originally published in PharmAsia News
Executive Summary
SillaJen, a private South Korean clinical-stage biotherapeutics company focused on the development of immunotherapies for cancer, is set to begin a global Phase III clinical trial with its candidate Pexa-Vec later this year, following an agreement with the U.S. FDA on a Special Protocol Assessment (SPA).